News

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company dedicated to developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases has announced the presentation of data from two translational studies demonstrating the ex vivo bioactivation of PALI-2108 in stool samples and whole blood. This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC).

10/31/2024

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA)

10/10/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Palisade Bio, Inc. (PALI) a buy, sell, or hold?

Palisade Bio, Inc. (PALI) can hold. Click on Rating Page for detail.

What is Palisade Bio, Inc.'s stock price?

The price of Palisade Bio, Inc. (PALI) is 2.58 and it was updated on 2024-11-06 13:00:53.

Is Palisade Bio, Inc. (PALI) overvalued or undervalued?

Currently Palisade Bio, Inc. (PALI) is in undervalued.

News

From:

To:

News
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update – Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end Tue, Aug. 13, 2024
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis – Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end Thu, Aug. 08, 2024
Palisade Bio Participates in Virtual Investor “What this Means” Segment Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108 Wed, Jul. 31, 2024
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108 Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients Mon, Jul. 29, 2024
Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108 Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition of Matter coverage beyond 2042 PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative Colitis (UC) PALI-1908 is in development to treat patients with active fibro stenotic Crohn's Disease (CD) Carlsbad, CA, July 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that European Patent Office (EPO) has issued a decision to grant notice for patent number 4,157,853 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” Based on the intention to grant notice, the Company expects the EPO to issue a patent July 31, 2024. Fri, Jul. 19, 2024

SEC Filings

SEC Filings
Palisade Bio, Inc. (PALI) - S-1 SEC Filings 10/30/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/27/2024
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/12/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/15/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/08/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/12/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/30/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/29/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/28/2024
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 05/22/2024
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 05/22/2024
Palisade Bio, Inc. (PALI) - ARS SEC Filings 05/22/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/22/2024
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 05/17/2024
Palisade Bio, Inc. (PALI) - 3 SEC Filings 05/16/2024
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/13/2024
Palisade Bio, Inc. (PALI) - D SEC Filings 05/10/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/10/2024
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 05/08/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/08/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/03/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/10/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/05/2024
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 04/05/2024
Palisade Bio, Inc. (PALI) - S-8 SEC Filings 03/29/2024
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 03/29/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/27/2024
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/26/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/12/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/06/2024
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/14/2024
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/13/2024
Palisade Bio, Inc. (PALI) - D SEC Filings 02/13/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/13/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/13/2024
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/09/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/08/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/07/2024
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/06/2024
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 02/06/2024
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 02/06/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/01/2024
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 02/01/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/01/2024
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/29/2024
Palisade Bio, Inc. (PALI) - RW SEC Filings 01/26/2024
Palisade Bio, Inc. (PALI) - PRE 14A SEC Filings 01/26/2024
Palisade Bio, Inc. (PALI) - 4 SEC Filings 01/05/2024
Palisade Bio, Inc. (PALI) - S-1 SEC Filings 12/29/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 12/19/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/24/2023
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/09/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/08/2023
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/07/2023
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/20/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 10/05/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/29/2023
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 09/15/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/15/2023
Palisade Bio, Inc. (PALI) - S-8 SEC Filings 09/14/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/14/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/13/2023
Palisade Bio, Inc. (PALI) - 3 SEC Filings 09/13/2023
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/11/2023
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 09/11/2023
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/08/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/14/2023
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/10/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/06/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/14/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/13/2023
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/09/2023
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/11/2023
Palisade Bio, Inc. (PALI) - S-1/A SEC Filings 04/27/2023
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 04/27/2023
Palisade Bio, Inc. (PALI) - S-1 SEC Filings 04/21/2023
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 04/21/2023
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 04/21/2023
Palisade Bio, Inc. (PALI) - ARS SEC Filings 04/21/2023
Palisade Bio, Inc. (PALI) - D SEC Filings 04/10/2023
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/05/2023
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 04/05/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/05/2023
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/22/2023
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/13/2023
Palisade Bio, Inc. (PALI) - 3 SEC Filings 02/15/2023
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/14/2023
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 02/14/2023
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/13/2023
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/08/2023
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/08/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/08/2023
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 01/25/2023
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 01/24/2023
Palisade Bio, Inc. (PALI) - D SEC Filings 01/19/2023
Palisade Bio, Inc. (PALI) - S-1 SEC Filings 01/13/2023
Palisade Bio, Inc. (PALI) - 4 SEC Filings 01/06/2023
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/04/2023
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 01/04/2023
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/16/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/23/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/16/2022
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/14/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/17/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/14/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/07/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/26/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/15/2022
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/02/2022
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 08/31/2022
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/25/2022
Palisade Bio, Inc. (PALI) - PRE 14A SEC Filings 08/23/2022
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 08/22/2022
Palisade Bio, Inc. (PALI) - PRE 14A SEC Filings 08/22/2022
Palisade Bio, Inc. (PALI) - POS462B SEC Filings 08/22/2022
Palisade Bio, Inc. (PALI) - POS EX SEC Filings 08/22/2022
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 08/18/2022
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/18/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/16/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/15/2022
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/15/2022
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 08/12/2022
Palisade Bio, Inc. (PALI) - POS EX SEC Filings 08/12/2022
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 08/12/2022
Palisade Bio, Inc. (PALI) - 424B4 SEC Filings 08/12/2022
Palisade Bio, Inc. (PALI) - S-1MEF SEC Filings 08/11/2022
Palisade Bio, Inc. (PALI) - S-1/A SEC Filings 08/11/2022
Palisade Bio, Inc. (PALI) - POS EX SEC Filings 08/11/2022
Palisade Bio, Inc. (PALI) - S-1/A SEC Filings 08/10/2022
Palisade Bio, Inc. (PALI) - S-1/A SEC Filings 08/09/2022
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 08/09/2022
Palisade Bio, Inc. (PALI) - S-1/A SEC Filings 08/02/2022
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 07/29/2022
Palisade Bio, Inc. (PALI) - FWP SEC Filings 07/25/2022
Palisade Bio, Inc. (PALI) - S-1/A SEC Filings 07/22/2022
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 07/05/2022
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 06/29/2022
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 06/28/2022
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 06/28/2022
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 06/24/2022
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 06/24/2022
Palisade Bio, Inc. (PALI) - S-1/A SEC Filings 06/22/2022
Palisade Bio, Inc. (PALI) - S-1 SEC Filings 06/22/2022
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 06/21/2022
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 06/20/2022
Palisade Bio, Inc. (PALI) - S-1 SEC Filings 06/14/2022
Palisade Bio, Inc. (PALI) - S-1 SEC Filings 06/13/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/10/2022
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 06/08/2022
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 06/07/2022
Palisade Bio, Inc. (PALI) - D SEC Filings 05/20/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/20/2022
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/13/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/06/2022
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 05/06/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/03/2022
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 05/02/2022
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/02/2022
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 04/27/2022
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 04/27/2022
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 04/27/2022
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 04/26/2022
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 04/22/2022
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 04/21/2022
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 04/21/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/20/2022
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/31/2022
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/29/2022
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/25/2022
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 03/24/2022
Palisade Bio, Inc. (PALI) - S-8 SEC Filings 03/18/2022
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 03/18/2022
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/17/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/16/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/24/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/23/2022
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/22/2022
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/14/2022
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 02/14/2022
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/11/2022
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/10/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/01/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/11/2022
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/10/2022
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 12/09/2021
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 12/09/2021
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 12/08/2021
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 12/03/2021
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 12/02/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/23/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/22/2021
Palisade Bio, Inc. (PALI) - S-8 SEC Filings 11/19/2021
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 11/19/2021
Palisade Bio, Inc. (PALI) - S-8 SEC Filings 11/18/2021
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 11/18/2021
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 11/18/2021
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/12/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/28/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/22/2021
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 10/08/2021
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 10/07/2021
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 10/07/2021
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 09/23/2021
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/22/2021
Palisade Bio, Inc. (PALI) - S-8 SEC Filings 09/15/2021
Palisade Bio, Inc. (PALI) - 10-Q/A - Quarterly Report SEC Filings 09/14/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/13/2021
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/13/2021
Palisade Bio, Inc. (PALI) - SC 13D SEC Filings 08/30/2021
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/30/2021
Palisade Bio, Inc. (PALI) - 3 SEC Filings 08/26/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/24/2021
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/23/2021
Palisade Bio, Inc. (PALI) - NT 10-Q - Quarterly Report SEC Filings 08/16/2021
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 08/11/2021
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 08/10/2021
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 08/10/2021
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 08/06/2021
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 08/05/2021
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 07/30/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/22/2021
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 07/13/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/09/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/16/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/01/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/26/2021
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/14/2021
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 05/11/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/06/2021
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/29/2021
Palisade Bio, Inc. (PALI) - 3 SEC Filings 04/29/2021
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 04/28/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/28/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/27/2021
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/26/2021
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 04/23/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 04/20/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 04/19/2021
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 04/15/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 04/14/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 04/13/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 04/12/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/09/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 04/05/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 04/02/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 03/30/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 03/29/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/24/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 03/24/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/23/2021
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/22/2021
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/18/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 03/18/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 03/17/2021
Palisade Bio, Inc. (PALI) - SEC STAFF LETTER SEC Filings 02/22/2021
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 02/12/2021
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 02/11/2021
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/11/2021
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 02/11/2021
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 02/10/2021
Palisade Bio, Inc. (PALI) - S-4/A SEC Filings 02/09/2021
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 02/09/2021
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 02/03/2021
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 01/29/2021
Palisade Bio, Inc. (PALI) - S-4/A SEC Filings 01/26/2021
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 01/26/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 01/25/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 01/20/2021
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 01/19/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 01/13/2021
Palisade Bio, Inc. (PALI) - SEC STAFF LETTER SEC Filings 01/08/2021
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 01/08/2021
Palisade Bio, Inc. (PALI) - 425 SEC Filings 01/08/2021
Palisade Bio, Inc. (PALI) - S-4 SEC Filings 12/23/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/21/2020
Palisade Bio, Inc. (PALI) - 425 SEC Filings 12/21/2020
Palisade Bio, Inc. (PALI) - 425 SEC Filings 12/17/2020
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 12/03/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/16/2020
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/10/2020
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 09/28/2020
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 09/24/2020
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 09/23/2020
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 09/22/2020
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 09/16/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/09/2020
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 09/02/2020
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 08/21/2020
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 08/20/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/14/2020
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/13/2020
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 08/10/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/10/2020
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 06/24/2020
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 06/24/2020
Palisade Bio, Inc. (PALI) - PRE 14A SEC Filings 06/12/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/12/2020
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 05/29/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/27/2020
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 05/27/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/21/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/15/2020
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/15/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/20/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/15/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/07/2020
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/07/2020
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 04/06/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/02/2020
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 04/01/2020
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 03/30/2020
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 03/27/2020
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 03/27/2020
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/27/2020
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 02/27/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/24/2020
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 02/20/2020
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 02/12/2020
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/11/2020
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/07/2020
Palisade Bio, Inc. (PALI) - D SEC Filings 01/28/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/23/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/22/2020
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 01/22/2020
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 01/21/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/16/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/10/2020
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/20/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/15/2019
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/14/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/04/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/30/2019
Palisade Bio, Inc. (PALI) - 4/A SEC Filings 10/11/2019
Palisade Bio, Inc. (PALI) - 3/A SEC Filings 10/11/2019
Palisade Bio, Inc. (PALI) - 3 SEC Filings 10/11/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/24/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/17/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/14/2019
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/14/2019
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 08/09/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/07/2019
Palisade Bio, Inc. (PALI) - 424B4 SEC Filings 07/29/2019
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 07/26/2019
Palisade Bio, Inc. (PALI) - S-1/A SEC Filings 07/25/2019
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 07/25/2019
Palisade Bio, Inc. (PALI) - S-1/A SEC Filings 07/24/2019
Palisade Bio, Inc. (PALI) - S-1/A SEC Filings 07/22/2019
Palisade Bio, Inc. (PALI) - FWP SEC Filings 07/22/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/18/2019
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/03/2019
Palisade Bio, Inc. (PALI) - 3 SEC Filings 07/03/2019
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 06/27/2019
Palisade Bio, Inc. (PALI) - 3 SEC Filings 06/27/2019
Palisade Bio, Inc. (PALI) - S-1 SEC Filings 06/21/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/18/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/03/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/14/2019
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/14/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/06/2019
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 04/29/2019
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 04/29/2019
Palisade Bio, Inc. (PALI) - PRE 14A SEC Filings 04/19/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/22/2019
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/22/2019
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/14/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/11/2019
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 01/07/2019
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/18/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/30/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/16/2018
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/14/2018
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 11/05/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/29/2018
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 10/29/2018
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 10/26/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/15/2018
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/13/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/09/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/05/2018
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/05/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/14/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/08/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/15/2018
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/15/2018
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 04/25/2018
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 04/25/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/02/2018
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 04/02/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/16/2018
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/09/2018
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 02/02/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/24/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/09/2018
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/20/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/05/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/15/2017
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/09/2017
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/08/2017
Palisade Bio, Inc. (PALI) - S-8 SEC Filings 10/04/2017
Palisade Bio, Inc. (PALI) - 3 SEC Filings 10/03/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/22/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/07/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/08/2017
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/08/2017
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 08/07/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/02/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/28/2017
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 07/28/2017
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 07/26/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/25/2017
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 07/19/2017
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 07/18/2017
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/18/2017
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 07/14/2017
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 07/13/2017
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 07/07/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/27/2017
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 06/26/2017
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 06/26/2017
Palisade Bio, Inc. (PALI) - 424B2 SEC Filings 06/26/2017
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 06/21/2017
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 06/21/2017
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 06/20/2017
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 06/08/2017
Palisade Bio, Inc. (PALI) - D SEC Filings 05/31/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/31/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/24/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/18/2017
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/18/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/12/2017
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/10/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/04/2017
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 05/01/2017
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 05/01/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/19/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/13/2017
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/13/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/12/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/31/2017
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/27/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/23/2017
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/23/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/20/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/10/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/28/2017
Palisade Bio, Inc. (PALI) - SC 13D SEC Filings 02/27/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/27/2017
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/27/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/22/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/16/2017
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/14/2017
Palisade Bio, Inc. (PALI) - 4 SEC Filings 01/27/2017
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/06/2017
Palisade Bio, Inc. (PALI) - 4 SEC Filings 12/30/2016
Palisade Bio, Inc. (PALI) - D SEC Filings 12/19/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/14/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/12/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/30/2016
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/28/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/08/2016
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/08/2016
Palisade Bio, Inc. (PALI) - 4 SEC Filings 10/27/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/21/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/20/2016
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/26/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/21/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/12/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/01/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/11/2016
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/11/2016
Palisade Bio, Inc. (PALI) - NT 10-Q - Quarterly Report SEC Filings 08/09/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/09/2016
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 08/01/2016
Palisade Bio, Inc. (PALI) - PRE 14A SEC Filings 07/21/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/23/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/21/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/20/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/16/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/13/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/10/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/07/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/06/2016
Palisade Bio, Inc. (PALI) - D SEC Filings 05/23/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/23/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/13/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/12/2016
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/09/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/04/2016
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 05/04/2016
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 05/02/2016
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 04/28/2016
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 04/28/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/22/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/13/2016
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/11/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/16/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/14/2016
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/14/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/04/2016
Palisade Bio, Inc. (PALI) - 3 SEC Filings 02/23/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/19/2016
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 02/16/2016
Palisade Bio, Inc. (PALI) - 4 SEC Filings 01/28/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/27/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/11/2016
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/08/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/20/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/16/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/16/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/10/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/09/2015
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/09/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/03/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 10/27/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 10/19/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 10/13/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 10/05/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/29/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/28/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/25/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/21/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/18/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/10/2015
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/10/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/27/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/24/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/23/2015
Palisade Bio, Inc. (PALI) - 25 SEC Filings 07/10/2015
Palisade Bio, Inc. (PALI) - CERTNAS SEC Filings 07/09/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/06/2015
Palisade Bio, Inc. (PALI) - 8-A12B SEC Filings 07/01/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/29/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/26/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/22/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/01/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/29/2015
Palisade Bio, Inc. (PALI) - 3 SEC Filings 05/21/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/11/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/08/2015
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/08/2015
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 04/27/2015
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 04/27/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/20/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/02/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/16/2015
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/16/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/12/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/03/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/02/2015
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 02/17/2015
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/09/2015
Palisade Bio, Inc. (PALI) - SC 13D/A SEC Filings 02/04/2015
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 02/02/2015
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 01/30/2015
Palisade Bio, Inc. (PALI) - 4 SEC Filings 12/30/2014
Palisade Bio, Inc. (PALI) - D/A SEC Filings 12/04/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/17/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/10/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/07/2014
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/07/2014
Palisade Bio, Inc. (PALI) - D SEC Filings 10/31/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/29/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/23/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/09/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/22/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/18/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/11/2014
Palisade Bio, Inc. (PALI) - 4/A SEC Filings 09/05/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/03/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/11/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/08/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/08/2014
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/08/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/07/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/05/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/04/2014
Palisade Bio, Inc. (PALI) - 3 SEC Filings 07/31/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/01/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/30/2014
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 06/20/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/18/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/11/2014
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 06/06/2014
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 06/02/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/02/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/23/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/12/2014
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/12/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/07/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/05/2014
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 04/29/2014
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 04/29/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/23/2014
Palisade Bio, Inc. (PALI) - PRE 14A SEC Filings 04/18/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/16/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/11/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/04/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/02/2014
Palisade Bio, Inc. (PALI) - S-8 SEC Filings 03/28/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/28/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/28/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/21/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/17/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/10/2014
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/10/2014
Palisade Bio, Inc. (PALI) - SC 13D SEC Filings 03/06/2014
Palisade Bio, Inc. (PALI) - 4/A SEC Filings 02/13/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/11/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/04/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/31/2014
Palisade Bio, Inc. (PALI) - 4 SEC Filings 01/27/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/17/2014
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 01/15/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/14/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/13/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/09/2014
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/06/2014
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 01/06/2014
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 12/06/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 12/05/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/13/2013
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/12/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/07/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/25/2013
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 10/25/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 10/21/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/10/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/23/2013
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 09/19/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/19/2013
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 09/16/2013
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 09/13/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/10/2013
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 09/10/2013
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 09/06/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/04/2013
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 08/30/2013
Palisade Bio, Inc. (PALI) - 144 SEC Filings 08/30/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/21/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/09/2013
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/08/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/02/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/22/2013
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 07/11/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/24/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/21/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/11/2013
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 06/05/2013
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 06/04/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/29/2013
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 05/24/2013
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 05/24/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/23/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/21/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/10/2013
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/10/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/09/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 05/09/2013
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 05/06/2013
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 04/30/2013
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 04/30/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/26/2013
Palisade Bio, Inc. (PALI) - 5 SEC Filings 04/26/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/23/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/22/2013
Palisade Bio, Inc. (PALI) - D SEC Filings 04/10/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/10/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/08/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/27/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/22/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/15/2013
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/15/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/26/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/21/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/20/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/15/2013
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 02/01/2013
Palisade Bio, Inc. (PALI) - 5 SEC Filings 01/30/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 01/23/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/16/2013
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 01/15/2013
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/09/2013
Palisade Bio, Inc. (PALI) - 4 SEC Filings 12/26/2012
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/27/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/09/2012
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/09/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/19/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/27/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/19/2012
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 09/14/2012
Palisade Bio, Inc. (PALI) - SC 13G/A SEC Filings 09/12/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/06/2012
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 08/22/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/17/2012
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 08/15/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/10/2012
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/09/2012
Palisade Bio, Inc. (PALI) - FWP SEC Filings 08/08/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/03/2012
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 08/03/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/27/2012
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/27/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/26/2012
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/22/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/20/2012
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/20/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/06/2012
Palisade Bio, Inc. (PALI) - DEFR14A SEC Filings 05/11/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/09/2012
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/09/2012
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 04/30/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/12/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/30/2012
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/30/2012
Palisade Bio, Inc. (PALI) - NT 10-K - Current report SEC Filings 03/15/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/09/2012
Palisade Bio, Inc. (PALI) - 5 SEC Filings 03/02/2012
Palisade Bio, Inc. (PALI) - 3/A SEC Filings 03/02/2012
Palisade Bio, Inc. (PALI) - SC 13G SEC Filings 02/16/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/08/2012
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 02/06/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/12/2012
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/27/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/08/2011
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/16/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/10/2011
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/09/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/25/2011
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 10/24/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/14/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/06/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/28/2011
Palisade Bio, Inc. (PALI) - 10-Q/A - Quarterly Report SEC Filings 09/23/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/13/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/11/2011
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/09/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/04/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/25/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/14/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/20/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/14/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/09/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/11/2011
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/10/2011
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 05/03/2011
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 04/27/2011
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 04/26/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/22/2011
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 04/20/2011
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 04/13/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/13/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/07/2011
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 03/31/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/16/2011
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/16/2011
Palisade Bio, Inc. (PALI) - S-8 SEC Filings 03/01/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/01/2011
Palisade Bio, Inc. (PALI) - 3 SEC Filings 02/25/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/15/2011
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 02/11/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/10/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/09/2011
Palisade Bio, Inc. (PALI) - 4/A SEC Filings 02/03/2011
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/03/2011
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/28/2011
Palisade Bio, Inc. (PALI) - 4 SEC Filings 12/29/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/16/2010
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 12/16/2010
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/23/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/22/2010
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 11/22/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/19/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/16/2010
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/15/2010
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 11/10/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/26/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/21/2010
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 10/21/2010
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 10/18/2010
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 10/15/2010
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 10/13/2010
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 10/08/2010
Palisade Bio, Inc. (PALI) - 10-K/A - Current report SEC Filings 10/05/2010
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/20/2010
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 09/17/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/15/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/13/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/10/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/27/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/18/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/17/2010
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/16/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/14/2010
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/12/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/30/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/29/2010
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 06/28/2010
Palisade Bio, Inc. (PALI) - DEFA14A SEC Filings 06/11/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/11/2010
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 06/04/2010
Palisade Bio, Inc. (PALI) - PRE 14A SEC Filings 06/01/2010
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 05/24/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/18/2010
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/17/2010
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 05/11/2010
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 05/07/2010
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 05/04/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/30/2010
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 04/27/2010
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 04/19/2010
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 04/19/2010
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 04/09/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/05/2010
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/31/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/19/2010
Palisade Bio, Inc. (PALI) - 5 SEC Filings 01/25/2010
Palisade Bio, Inc. (PALI) - D SEC Filings 01/05/2010
Palisade Bio, Inc. (PALI) - 4 SEC Filings 01/04/2010
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/29/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/21/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/17/2009
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/16/2009
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/25/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/21/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/21/2009
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/14/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/13/2009
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/22/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/01/2009
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 06/30/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/05/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/01/2009
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 05/28/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/15/2009
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/15/2009
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/20/2009
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 04/07/2009
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 04/06/2009
Palisade Bio, Inc. (PALI) - 4/A SEC Filings 04/03/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/02/2009
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 04/01/2009
Palisade Bio, Inc. (PALI) - 10-K - Current report SEC Filings 03/31/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/09/2009
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 03/02/2009
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 03/02/2009
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 02/26/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/20/2009
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 02/17/2009
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 02/11/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/10/2009
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 02/03/2009
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 02/02/2009
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/29/2009
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 01/22/2009
Palisade Bio, Inc. (PALI) - 4 SEC Filings 12/31/2008
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 12/18/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/18/2008
Palisade Bio, Inc. (PALI) - 424B5 SEC Filings 12/18/2008
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 12/16/2008
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 12/04/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 12/03/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/18/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/14/2008
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 11/13/2008
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 09/30/2008
Palisade Bio, Inc. (PALI) - S-3/A SEC Filings 09/26/2008
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 09/09/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/09/2008
Palisade Bio, Inc. (PALI) - 4 SEC Filings 08/22/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/15/2008
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 08/14/2008
Palisade Bio, Inc. (PALI) - S-8 SEC Filings 08/06/2008
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 08/06/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 07/31/2008
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/10/2008
Palisade Bio, Inc. (PALI) - 4 SEC Filings 07/07/2008
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/05/2008
Palisade Bio, Inc. (PALI) - 4 SEC Filings 06/02/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/15/2008
Palisade Bio, Inc. (PALI) - 10-Q - Quarterly Report SEC Filings 05/15/2008
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 05/13/2008
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 05/13/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/12/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/06/2008
Palisade Bio, Inc. (PALI) - S-3 SEC Filings 05/01/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/01/2008
Palisade Bio, Inc. (PALI) - DEF 14A SEC Filings 04/24/2008
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/24/2008
Palisade Bio, Inc. (PALI) - 3/A SEC Filings 04/18/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/16/2008
Palisade Bio, Inc. (PALI) - PRE 14A SEC Filings 04/14/2008
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/03/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/28/2008
Palisade Bio, Inc. (PALI) - 10KSB SEC Filings 03/27/2008
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/11/2008
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/25/2008
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/22/2008
Palisade Bio, Inc. (PALI) - 5 SEC Filings 02/14/2008
Palisade Bio, Inc. (PALI) - 4 SEC Filings 02/12/2008
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 01/02/2008
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 01/02/2008
Palisade Bio, Inc. (PALI) - POS AM SEC Filings 12/20/2007
Palisade Bio, Inc. (PALI) - AW SEC Filings 12/20/2007
Palisade Bio, Inc. (PALI) - POS462C SEC Filings 12/11/2007
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/30/2007
Palisade Bio, Inc. (PALI) - 4 SEC Filings 11/19/2007
Palisade Bio, Inc. (PALI) - 10QSB SEC Filings 11/13/2007
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 11/08/2007
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 11/01/2007
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 11/01/2007
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 10/26/2007
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 10/16/2007
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/24/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 09/21/2007
Palisade Bio, Inc. (PALI) - 4 SEC Filings 09/21/2007
Palisade Bio, Inc. (PALI) - 3 SEC Filings 09/05/2007
Palisade Bio, Inc. (PALI) - 3 SEC Filings 09/04/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 08/27/2007
Palisade Bio, Inc. (PALI) - CERTAMX SEC Filings 08/24/2007
Palisade Bio, Inc. (PALI) - 8-A12B SEC Filings 08/23/2007
Palisade Bio, Inc. (PALI) - 10QSB SEC Filings 08/14/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/27/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 06/06/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/30/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 05/21/2007
Palisade Bio, Inc. (PALI) - 10QSB SEC Filings 05/15/2007
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 05/07/2007
Palisade Bio, Inc. (PALI) - 424B4 SEC Filings 05/07/2007
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 05/03/2007
Palisade Bio, Inc. (PALI) - SB-2 SEC Filings 04/30/2007
Palisade Bio, Inc. (PALI) - 4 SEC Filings 04/26/2007
Palisade Bio, Inc. (PALI) - 3 SEC Filings 04/26/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/25/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 04/10/2007
Palisade Bio, Inc. (PALI) - 10KSB SEC Filings 04/02/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/27/2007
Palisade Bio, Inc. (PALI) - REGDEX/A SEC Filings 03/21/2007
Palisade Bio, Inc. (PALI) - 4 SEC Filings 03/19/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 03/16/2007
Palisade Bio, Inc. (PALI) - 5 SEC Filings 02/16/2007
Palisade Bio, Inc. (PALI) - 5/A SEC Filings 02/13/2007
Palisade Bio, Inc. (PALI) - 3/A SEC Filings 02/09/2007
Palisade Bio, Inc. (PALI) - 3/A SEC Filings 02/07/2007
Palisade Bio, Inc. (PALI) - 8-K/A - Current report SEC Filings 02/06/2007
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 02/05/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 02/02/2007
Palisade Bio, Inc. (PALI) - 5 SEC Filings 01/29/2007
Palisade Bio, Inc. (PALI) - 3 SEC Filings 01/29/2007
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 01/08/2007
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 01/04/2007
Palisade Bio, Inc. (PALI) - 10QSB SEC Filings 11/17/2006
Palisade Bio, Inc. (PALI) - NT 10-Q - Quarterly Report SEC Filings 11/15/2006
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 11/13/2006
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 11/06/2006
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 11/06/2006
Palisade Bio, Inc. (PALI) - 8-K - Current report SEC Filings 10/17/2006
Palisade Bio, Inc. (PALI) - 424B3 SEC Filings 10/04/2006
Palisade Bio, Inc. (PALI) - EFFECT SEC Filings 08/31/2006
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 08/30/2006
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 08/29/2006
Palisade Bio, Inc. (PALI) - SB-2/A SEC Filings 08/28/2006
Palisade Bio, Inc. (PALI) - SB-2/A SEC Filings 08/25/2006
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 08/24/2006
Palisade Bio, Inc. (PALI) - SB-2/A SEC Filings 08/22/2006
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 08/17/2006
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 08/15/2006
Palisade Bio, Inc. (PALI) - SB-2/A SEC Filings 08/10/2006
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 08/04/2006
Palisade Bio, Inc. (PALI) - SB-2/A SEC Filings 07/26/2006
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 07/05/2006
Palisade Bio, Inc. (PALI) - SB-2/A SEC Filings 06/21/2006
Palisade Bio, Inc. (PALI) - CORRESP SEC Filings 06/21/2006
Palisade Bio, Inc. (PALI) - UPLOAD SEC Filings 04/28/2006
Palisade Bio, Inc. (PALI) - SB-2 SEC Filings 04/03/2006

Press Releases

StockPrice Release
Palisade bio announces positive data from two ex vivo translational studies of pali-2108 for the treatment of ulcerative colitis 10/31/2024
Palisade bio cleared by health canada to commence phase 1 clinical study for lead program, pali-2108 for the treatment of ulcerative colitis (uc) 10/10/2024
Palisade bio reports second quarter 2024 financial results and provides business update 08/13/2024
Palisade bio selects dose for upcoming phase 1 clinical study of pali-2108 for ulcerative colitis 08/08/2024
Palisade bio participates in virtual investor “what this means” segment 07/31/2024
Palisade bio successfully completes microbiome study confirming bacterial enzymes for local bioactivation of lead product candidate, pali-2108 07/29/2024
Palisade bio announces european patent office issued a decision to grant notice for patent for lead product candidate, pali-2108 07/19/2024
Palisade bio announces successful completion of first gmp manufacturing of pali-2108 drug substance and engineering batches of drug product 07/11/2024
Palisade bio to participate in the virtual investor closing bell series 06/24/2024
Palisade bio provides update on advancement of its strategic collaboration with strand life sciences 06/21/2024
Palisade bio announces notice of allowance for canadian patent covering lead product candidate, pali-2108 06/11/2024
Palisade bio to present at the virtual investor pitch conference 06/10/2024
Palisade bio's lead product candidate, pali-2108 demonstrates local bioactivation and dose dependent efficacy response in preclinical mouse models 05/21/2024
Palisade bio reports first quarter 2024 financial results and provides business update 05/14/2024
Palisade bio appoints margery fischbein to its board of directors 05/07/2024
Palisade bio announces closing of $4 million private placement priced at-the- market under nasdaq rules 05/07/2024
Palisade bio announces $4 million private placement priced at-the- market under nasdaq rules 05/02/2024
Palisade bio's lead product candidate, pali-2108 demonstrates potent anti-inflammatory effects in ex-vivo study of whole blood samples challenged with pro-inflammatory lipopolysaccharide (lps) 05/01/2024
Palisade bio enters into strategic collaboration with strand life sciences to advance precision medicine approach 04/23/2024
Palisade bio successfully demonstrates bioactivation of pali-2108 in ex-vivo study of normal healthy and ulcerative colitis patients' stool 04/16/2024
Palisade bio to participate in the virtual investor lunch break event 04/11/2024
Palisade bio presents development overview of pali-2108 at the ibd innovate: product development for crohn's & colitis™ 04/10/2024
Palisade bio announces 1-for-15 reverse stock split 04/03/2024
Palisade bio to present at digestive disease week (ddw) 2024 02/15/2024
Palisade bio provides corporate update and reiterates guidance 02/13/2024
Correction notice of palisade bio's press release announcing the appointment of clinical advisory board members 02/08/2024
Palisade bio announces formation of clinical advisory board with appointments of preeminent key opinion leaders 02/08/2024
Palisade bio announces positive preclinical data of lead program pali-2108 at the 2024 crohn's & colitis congress 01/29/2024
Palisade bio announces receipt of second milestone payment from the us crohn's and colitis foundation for development of pali-2108 12/28/2023
Palisade bio reports third quarter 2023 financial results and provides business outlook 11/10/2023
Palisade bio to participate at the virtual investor ask the ceo conference 10/11/2023
Palisade bio announces closing of $2 million registered direct offering priced at market under nasdaq rules 09/11/2023
Palisade bio appoints gi clinical expert and biotech entrepreneur mitchell jones, m.d., ph.d. as chief medical officer 09/11/2023
Palisade bio announces $2 million registered direct offering of common stock priced at market under nasdaq rules 09/07/2023
Palisade bio transforms gi-focused pipeline through exclusive worldwide licensing agreement with giiant pharma, inc. for multiple oral drug candidates targeting inflammatory bowel disease 09/06/2023
Palisade bio reports second quarter 2023 financial results 08/11/2023
Palisade bio announces topline results from u.s. phase 2 profile study evaluating lb1148 for post-surgical abdominal adhesions 08/09/2023
Palisade bio announces completion of enrollment in lb1148 dose optimization study 07/05/2023
Palisade bio participate in the healthcare virtual conference presented by maxim group llc and hosted by m-vest 06/14/2023
Palisade bio's lb1148 two ongoing clinical trials expecting topline data readouts 05/24/2023
Palisade bio reports first quarter 2023 financial results 05/12/2023
Palisade bio announces enrollment and dosing of first patient in lb1148 dose optimization study 05/11/2023
Palisade bio receives canadian patent covering composition of lead program in development, lb1148 04/06/2023
Palisade bio announces enrollment of first patient in newsoara phase 3 clinical trial evaluating lb1148 04/05/2023
Palisade bio reports year end 2022 financial results and provides corporate update 03/23/2023
Palisade bio receives intention to grant from european patent office for lb1148 patent 03/01/2023
Palisade bio promotes robert mcrae to chief operating officer 02/08/2023
Palisade bio further strengthens balance sheet with early exercise of warrants resulting in cash proceeds of $4.9 million 01/10/2023
Palisade bio to present at the virtual investor 2023 companies to watch event 01/09/2023
Palisade bio announces closing of $2.5 million registered direct offering and concurrent private placement priced above market under nasdaq rules 01/04/2023
Palisade bio announces $2.5 million registered direct offering and concurrent private placement priced above market under nasdaq rules 12/30/2022
Palisade bio provides update on u.s. phase 2 study evaluating lb1148 for post-surgical abdominal adhesions 12/16/2022
Palisade bio announces early exercise of warrants resulting in cash proceeds of $1.25 million 12/07/2022
Palisade bio regains compliance with nasdaq listing requirements 12/01/2022
Palisade bio is granted fast track designation from the u.s. food and drug administration for lb1148 for accelerated return of bowel function following gi surgery 11/22/2022
Palisade bio appoints herbert b. slade, md, faaaai as chief medical officer 11/18/2022
Palisade bio announces reverse stock split 11/15/2022
Palisade bio reports third quarter 2022 financial results and provides business update 11/14/2022
Palisade bio announces executive leadership transition 10/11/2022
Palisade bio announces oral presentation of phase 2 data at the american college of surgeons (acs) clinical congress 2022 09/29/2022
Palisade bio announces inducement grants under nasdaq listing rule 5635(c)(4) 09/23/2022
Palisade bio to present at the ladenburg thalmann 2022 healthcare conference 09/21/2022
Palisade bio streamlines operations and identifies capital efficiencies to focus all resources on advancement of lead clinical program, lb1148 09/15/2022
Palisade bio to present at the virtual investor innovations in intestinal health - launching a pivotal phase 3 study for return of postoperative bowel function event 09/13/2022
Palisade bio announces first patient enrolled and dosed in pivotal phase 3 study evaluating lb1148 for postoperative return of bowel function 08/17/2022
Palisade bio announces closing of $13.8 million upsized underwritten public offering and full exercise of over-allotment option 08/16/2022
Palisade bio announces pricing of $12 million upsized underwritten public offering 08/12/2022
Palisade bio launches new corporate website and reiterates commitment to develop therapeutics that protect intestinal barrier health 08/01/2022
Palisade bio announces first patient screened in phase 3 study evaluating lb1148 for postoperative return of bowel function 07/27/2022
Palisade bio initiates phase 3 study of lb1148 in lead indication for postoperative return of bowel function 06/29/2022
Palisade bio to present at the 2022 bio international convention 06/07/2022
Palisade bio reports first quarter 2022 financial results and provides corporate update 05/13/2022
Palisade bio announces inducement awards under inducement plan for key new hires 05/10/2022
Palisade bio announces $2.0 million registered direct offering 05/06/2022
Palisade bio provides business outlook and highlights expected near-term pipeline advancements 05/02/2022
Palisade bio to participate in the virtual investor management and kol roundtable event 04/29/2022
Palisade bio (nasdaq: pali) to participate in the 2022 virtual growth conference presented by maxim group and hosted by m-vest 03/24/2022
Palisade bio (nasdaq: pali) receives fda “study may proceed” letter for pivotal phase 3 clinical trial evaluating lb1148 to accelerate the return of bowel function following abdominal surgery 03/22/2022
Palisade bio (nasdaq: pali) reports year end 2021 financial results and corporate update 03/18/2022
Palisade bio (nasdaq: pali) announces analysis demonstrating lb1148 reduced the extent and severity of post-surgical intraabdominal adhesions by 93% 03/16/2022
Preventing post-surgical abdominal adhesions: virtual presentation on palisade bio's lb1148 clinical data; to be hosted & moderated by stonegate capital partners 03/14/2022
Palisade bio (nasdaq: pali) to present at the biocom global life science partnering conference 02/18/2022
Palisade bio (nasdaq: pali) adds pharmaceutical industry executive robert mcrae to leadership team 02/15/2022
Palisade bio (nasdaq: pali) to announce adhesions clinical data at sages 2022 annual meeting 02/08/2022
Palisade bio to present at the h.c. wainwright bioconnect virtual conference and biotech showcase 12/29/2021
Palisade bio granted new u.s. patent covering protease inhibitor lb1148 for treating adhesions and postoperative ileus 12/08/2021
Palisade bio announces inducement awards under inducement plan for key new hires, including nick mccoy, vice president of clinical operations 11/23/2021
Palisade bio, inc. announces sale of seneca asset nsi-189 for the treatment of central nervous system disorders 10/22/2021
Palisade bio reports second quarter financial results and provides business update 08/24/2021
Palisade bio announces $5.2m investment by the yuma regional medical center 08/20/2021
Palisade bio and newsoara announce positive topline efficacy results from phase 2 study of lb1148 demonstrating accelerated return of bowel function after gastrointestinal surgery 07/29/2021
Palisade bio launches clinical steering committee to provide clinical oversight and guide preparation for late-stage clinical trials of lb1148 in accelerating postoperative return of bowel function and reduction of post-surgical adhesions 06/15/2021
Palisade bio receives fda fast track designation for lb1148 for reduction of adhesions following abdominal and pelvic surgery 05/13/2021
Palisade bio and newsoara announce completion of phase 2 study in gi surgery study in china 05/07/2021

More Headlines

News
Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) before year end Carlsbad, CA, July 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the successful completion of the first Good Manufacturing Practice (GMP) batch of its drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC. The GMP manufacturing was conducted in partnership with Eurofins, a contract development and manufacturing organization. 07/11/2024
Palisade Bio to Participate in the Virtual Investor Closing Bell Series Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, June 26, 2024 at 4:00 PM ET. As part of the event, J.D. 06/24/2024
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences – Collaboration advancing Palisade Bio's precision medicine approach through access to cutting-edge expertise and tools in bioinformatics 06/21/2024
Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now Palisade Bio (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. 06/14/2024
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108 PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for patent application number 3,174,137 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” This patent covers the composition of PALI-2108, the Company's orally administered, locally acting colon-specific Phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by Ulcerative Colitis (UC). 06/11/2024
Palisade Bio to Present at the Virtual Investor Pitch Conference Live video webcast on Monday, June 17 th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 12:00 PM ET. As part of the event, J.D. 06/10/2024
Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure PALI-2108 exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human use in Ulcerative Colitis (UC) patients Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of UC before year end Carlsbad, CA, May 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the presentation of positive preclinical data from PALI-2108, an orally administered, locally acting colon-specific Phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC, at DDW 2024 being held in Washington, D.C., May 18-21, 2024. 05/21/2024
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update – Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end 05/14/2024
Palisade Bio Appoints Margery Fischbein to its Board of Directors Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally 05/07/2024
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its previously announced private placement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu thereof) for gross proceeds of approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company. 05/07/2024
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has entered into a definitive agreement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu thereof) in a private placement at a purchase price per share of $6.5015, priced at-the-market under Nasdaq rules. The Company expects to receive gross proceeds of approximately $4 million, before deducting placement agent fees and other offering expenses payable by the Company. 05/02/2024
Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end 05/01/2024
Palisade Bio stock rallies on Strand Life Sciences partnership Palisade Bio Inc (NASDAQ: PALI) opened roughly 50% up on Tuesday after teaming up with Strand Life Sciences. Here's what it means for Palisade Bio stock The strategic collaboration puts its patient datasets together with bioinformatics tools of the genomics software and services company. 04/23/2024
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach – Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics – Partnership marks a significant value-driving milestone in Palisade Bio's mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers Carlsbad, CA, April 23, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has entered into a transformative strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy. The collaboration with Strand Life Sciences provides Palisade Bio access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors. 04/23/2024
Why Is Palisade Bio (PALI) Stock Up 57% Today? Palisade Bio (NASDAQ: PALI ) stock is climbing higher on Tuesday after the clinical-stage biopharmaceutical company revealed additional data for its ulcerative colitis (UC) treatment. The big news here is Palisade Bio completing its analysis of ex-vivo bioactivation of PALI-2108. 04/16/2024
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, announced today the successful completion of its analysis evaluating ex-vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC. These findings demonstrated that PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with UC. 04/16/2024
Palisade Bio to Participate in the Virtual Investor Lunch Break Event – Live webcast with members of Palisade Bio management on Tuesday, April 16 th at 12:00 PM ET 04/11/2024
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis™ – PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end 04/10/2024
Palisade Bio Announces 1-for-15 Reverse Stock Split Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced a 1-for-15 reverse split of its common stock, par value $0.01 (“Common Stock”), effective at 5:00 PM ET on Friday April 5, 2024. Beginning on Monday, April 8, 2024, the Company's Common Stock will continue to trade on The Nasdaq Capital Market (“Nasdaq”) on a split adjusted basis under the trading symbol “PALI,” but will trade under the following new CUSIP number starting April 8, 2024: 696389402. 04/03/2024
Palisade Bio to Present at Digestive Disease Week (DDW) 2024 Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that its abstract has been accepted for poster presentation at DDW 2024 being held in Washington, D.C., May 18-21, 2024. 02/15/2024
Palisade Bio Provides Corporate Update and Reiterates Guidance – Company announces strategic streamlining of Board to align with the current state of clinical development and corporate vision 02/13/2024
Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced a correction to its press release originally issued on February 8, 2024, announcing the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). 02/08/2024
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders Carlsbad, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the appointments of Bruce Sands, MD, MS and Florian Rieder, MD to its Clinical Advisory Board (CAB). Drs. Sands and Rieder will be advising Palisade on the advancement of its product candidates from preclinical studies to clinical trials. 02/08/2024
Why Is Palisade Bio (PALI) Stock Up 100% Today? Biopharmaceutical company Palisade Bio (NASDAQ: PALI ) is seeing its market value skyrocket off multiple encouraging catalysts today. While PALI stock still remains an extremely risky proposition, investors are being buoyed by some key developments. 01/29/2024
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress – Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – Company advancing PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) toward Phase 1 clinical study, expected to commence in 2024 Carlsbad, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced the presentation of positive preclinical data of its lead asset, PALI-2108 at the Crohn's & Colitis Congress, which was held on January 25-27, 2024 in Las Vegas, NV. The preclinical data was presented in a poster titled, Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment. 01/29/2024
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108 - Company's co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn's and Colitis Foundation 12/28/2023
Why Is Palisade Bio (PALI) Stock Down 46% Today? Palisade Bio (NASDAQ: PALI ) stock is falling on Thursday after the clinical-stage biopharmaceutical company announced a share offering. Palisade Bio is selling 2,339,398 shares of PALI stock through a registered direct offering. 09/07/2023
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up Palisade (PALI) gains on entering into global licensing deal with Giiant Pharma to develop gastrointestinal therapies. 09/07/2023
Palisade Bio's stock more than doubles on news of licensing deal with Giiant Pharma for IBD therapies Palisade Bio Inc.'s stock PALI more than doubled in price on Wednesday, after the company announced a licensing agreement with privately held Giiant Pharma Inc. Carlsbad, Calif.-based Palisade said the license gives it exclusive worldwide rights to develop, make and commercialize Giiant's proprietary targeted prodrug platform which specializes in therapies for the IBS market. 09/06/2023
Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest Live webcast fireside chat on Thursday, June 22 nd at 11:30 AM ET 06/14/2023
Palisade Bio, Inc. (PALI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now Palisade Bio, Inc. (PALI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. 05/23/2023
Palisade (PALI) Enrolls First Patient in LB1148 Study in China Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China. 04/06/2023
Why Is Palisade Bio (PALI) Stock Up 36% Today? Palisade Bio (NASDAQ: PALI ) stock is on the rise Friday after the biopharmaceutical company got an upgrade from an analyst. Maxim Group is behind today's upgrade for PALI stock. 03/31/2023
What Makes Palisade Bio, Inc. (PALI) a New Buy Stock Palisade Bio, Inc. (PALI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 03/29/2023
Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event Live video webcast on Tuesday, January 17 th at 3:00 PM ET 01/09/2023
Trading Penny Stocks in the New Year? 3 Tips Which penny stocks are you buying this year? The post Trading Penny Stocks in the New Year? 01/03/2023
How to Increase Your Chances of Consistent Penny Stocks Profits Use these tips to make money with penny stocks The post How to Increase Your Chances of Consistent Penny Stocks Profits appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 01/01/2023
Palisade Bio's (PALI) LB1148 Gets FDA Fast-Track Designation Palisade Bio (PALI) gets Fast Track status from the FDA for its lead drug, LB1148, for accelerated return of bowel function following gastrointestinal (GI) surgery. 11/23/2022
Should You Be Buying Penny Stocks? Here's 3 Reasons Why Check out these tips for trading penny stocks The post Should You Be Buying Penny Stocks? Here's 3 Reasons Why appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 11/23/2022
Why Is Palisade Bio (PALI) Stock Up 130% Today? On another low-volume day heading into Thanksgiving, investors have something to be thankful for. There's green on the screen in most sectors, with stocks staging a nice rally. 11/22/2022
Palisade Bio (PALI) Stock: Reverse Split Announced The Palisade Bio (PALI) board has announced a reverse stock split. These are the details. 11/15/2022
Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET Live video webcast fireside chat on Thursday, September 29th at 11:30 AM ET 09/21/2022
Palisade Bio to Present at the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel Function Event Live moderated video webcast with members of Management to discuss pivotal Phase 3 study of lead asset in development, LB1148, on Friday, September 16th at 11:00 AM ET Live moderated video webcast with members of Management to discuss pivotal Phase 3 study of lead asset in development, LB1148, on Friday, September 16th at 11:00 AM ET 09/13/2022
Palisade Bio, Inc. (PALI) Moves to Buy: Rationale Behind the Upgrade Palisade Bio, Inc. (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 08/25/2022
Top Penny Stocks To Buy? 4 For Your Watch List Before Next Week Penny stocks under $1 to watch this week. The post Top Penny Stocks To Buy? 08/25/2022
Hot Penny Stocks to Add to Your Watchlist Right Now Here's what you need to know about buying penny stocks on August 19th The post Hot Penny Stocks to Add to Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 08/19/2022
Cheap Penny Stocks to Buy Now? 3 To Watch in August Here's what you need to know about buying penny stocks on August 18th The post Cheap Penny Stocks to Buy Now? 3 To Watch in August appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 08/18/2022
Palisade Bio to Present at the 2022 BIO International Convention In-person presentation on Monday, June 13th at 1:45 PM PT In-person presentation on Monday, June 13th at 1:45 PM PT 06/07/2022
Top Penny Stocks Today: Why DPRO, PALI, ENSV, SPCB and SMFL Are Up Today We're seeing a lot of activity from penny stocks today and have put together a list of the top ones for investors to watch. The post Top Penny Stocks Today: Why DPRO, PALI, ENSV, SPCB and SMFL Are Up Today appeared first on InvestorPlace. 03/22/2022
FDA Gives Green Signal For Palisade Bio's LB1148 Phase 3 Study Palisade Bio Inc (NASDAQ: PALI) has received a "Study May Proceed" letter from the FDA for a Phase 3 trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowel/abdominal surgery. The trial will enroll approximately 600 subjects. 03/22/2022
Trading Penny Stocks? Top Stock Market News for March 22nd, 2022 What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for March 22nd, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 03/22/2022
Palisade Bio's LB1148 Cuts The Risk of Adhesion Formation By 72% After Bowel Resection Surgery Palisade Bio Inc (NASDAQ: PALI) announced data from a Pooled-Analysis of Studies LBS-IST-POI-101 and LBS-POI-201-CN (PROFILE-CN), highlighting LB1148 reduced incidence of adhesions by 72% in patients undergoing bowel resection. Studies assessed the efficacy of LB1148 to reduce the. 03/16/2022
Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference CARLSBAD, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, will present at the Biocom Global Life Science Partnering Conference in San Diego on Thursday, February 24, 2022. Palisade Bio's Chief Executive Officer, Tom Hallam, Ph.D., is scheduled to present an updated presentation at 11:30 a.m. Pacific Time. Palisade Bio's presentation can be accessed at on our website at www.palisadebio.com/investors. 02/18/2022
Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148 Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148 02/08/2022
Best Penny Stocks To Buy This Week? 5 Names You Should Know Now Here are 5 penny stocks to watch this week The post Best Penny Stocks To Buy This Week? 5 Names You Should Know Now appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 02/06/2022
4 Penny Stocks To Buy Now According To Analysts, Targets Over 300% Are these on your list of the best penny stocks to buy right now? Here's what analysts think The post 4 Penny Stocks To Buy Now According To Analysts, Targets Over 300% appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 02/02/2022
Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase CARLSBAD, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announces that they will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022, and at Biotech Showcase taking place January 10-12, 2022. The Palisade Bio management team also will be hosting investor meetings during that period and talking about their lead program, LB1148. LB1148 has shown significant results in a Phase 2 trial with a 1.1-day improvement in return to bowel function following GI surgery in the mean. 12/29/2021
Palisade Bio: Guarding Intestinal Integrity Palisade Bio is developing oral therapies targeting protease inhibition in GI diseases. The Company's lead candidate LB1148 showed promising data in Phase 2 trials. 11/07/2021
Palisade Bio Reports Second Quarter Financial Results and Provides Business Update CARLSBAD, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today provides a business update and releases its financial results for the second quarter ending June 30, 2021. 08/24/2021
Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center CARLSBAD, Calif., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a late‐stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announces a new private investment of approximately $5.2 million from the Yuma Regional Medical Center ("YRMC"), an Arizona‐based, not‐for‐profit hospital providing high‐quality, patient‐centered care. The funds will be used to advance the clinical development of Palisade's lead oral liquid drug candidate LB1148, which is being developed to accelerate the return of bowel function after surgery and to reduce post‐surgical adhesions. 08/20/2021
PALI Stock Increases Over 16% Pre-Market: Why It Happened The stock price of Palisade Bio Inc (NASDAQ: PALI) increased by over 16% pre-market. This is why it happened. 07/29/2021
Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery Statistically significant 1.1-day acceleration in return of bowel function 07/29/2021
Palisade Bio, University of California Team Up For Target Identification, Discovery, Development Palisade Bio Inc (NASDAQ: PALI) has entered into an exclusive license with the Regents of the University of California, expanding its technology for detecting enzymatic protease activity in human clinical samples. Under the terms of this agreement, the Company receives a worldwide exclusive license to patent rights covering certain engineered substrates and their use in measuring degradative enzymes for disease conditions. 07/13/2021
Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions Former Leading BioSciences Chairman and Retired Board-Certified Surgeon, Dr. David Berry to Serve as Chair Former Leading BioSciences Chairman and Retired Board-Certified Surgeon, Dr. David Berry to Serve as Chair 06/15/2021
Palisade Bio Stock Shoots Up On FDA Fast Track Tag For LB1148 For Reduction of Post-Operative Adhesions The FDA has granted Fast Track Designation to Palisade Bio Inc's (NASDAQ: PALI) investigational drug LB1148, which has the potential to be the first oral treatment to reduce adhesions following abdominal or pelvic surgery. LB1148 was previously granted Fast Track Designation to treat postoperative GI dysfunction associated with pediatric cardiovascular surgery. 05/13/2021
Palisade Bio (PALI) Stock: Over 25% Increase Pre-Market Explanation The stock price of Palisade Bio, Inc. (Nasdaq: PALI) increased by over 25% pre-market. This is why it happened. 05/13/2021
Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery LB1148 was previously granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of postoperative GI dysfunction associated with pediatric cardiovascular surgery 05/13/2021
Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China Topline results expected in H1-2021 Topline results expected in H1-2021 05/07/2021

Unlock

PALI Ratings Summary

PALI Quant Ranking